Form 4: Akari Therapeutics CEO Rachelle Jacques Acquires Shares Through Restricted Stock Units

Akari Therapeutics CEO Rachelle Jacques acquired 479,569,892 ordinary shares through restricted stock units on April 26, 2024.

Summary

• On April 26, 2024, Rachelle Jacques, CEO of Akari Therapeutics Plc, acquired 479,569,892 ordinary shares.
• The acquisition was through restricted stock units (RSUs), each representing the right to receive one ordinary share.
• 50% of the RSUs will vest on March 28, 2025, and the remaining portion will vest in 12 equal monthly installments thereafter.
• Vesting is contingent upon Jacques' continued service with Akari Therapeutics.
• Following the transaction, Jacques directly owns 1,018,027,792 ordinary shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The CEO receiving RSUs is a standard practice and aligns her interests with shareholders. It indicates confidence in the company's future.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future.

Future Outlook

The vesting schedule of the RSUs incentivizes the CEO to remain with the company and drive long-term value.

Industry Context

This type of equity compensation is common for executives in publicly traded companies to align their interests with those of shareholders.

Comparison to Industry Standards

• Granting restricted stock units to executives is a standard practice in the biotechnology industry, similar to companies like Amgen, Biogen, and Gilead Sciences.
• The vesting schedule is also typical, with vesting periods ranging from one to four years, contingent on continued employment.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates